Personalized cell therapy involves extracting immune cells from patients, modifying them genetically, and reinfusing them to fight various diseases. It is majorly used to treat cancer by modifying T-cells extracted from patients to attack cancerous cells specifically. Personalized cell therapy relies on precise molecular profiling of patient and disease characteristics to develop a unique treatment approach tailored for each individual. Various cell therapies including chimeric antigen receptor T-cell (CAR T-cell) therapy and T-cell receptor therapy have shown promising results in treating hematological cancers and solid tumors. The increasing success of CAR T-cell therapies in clinical trials for blood cancers like acute lymphoblastic leukemia and lymphoma is driving their adoption in oncology.
The global personalized cell therapy market is estimated to be valued at US$ 5.56 Bn in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The growing adoption of personalized cell therapy in oncology therapeutics is one of the major drivers of this market. As highlighted in the heading, CAR T-cell therapies have gained US FDA approval for indications like leukemia and lymphoma due to high response rates in clinical trials. Additionally, the emergence of next-generation CAR T-cell therapies with improved potency and safety is expected to further drive their utilization in cancer treatment. Another driver is the rising prevalence of cancer worldwide. According to WHO estimates, cancer burden is expected to rise to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. This growing cancer patient pool indicates a corresponding increase in demand for advanced therapies like personalized cell therapy.
The global personalized cell therapy market is dominated by the autologous CAR-T cells sub-segment due to its efficacy in the treatment of cancer patients. Autologous CAR-T cells are preferred in cancer immunotherapy as the T-cells extracted from the patient’s own body are genetically engineered to attack tumour cells specifically. This personalized approach results in higher efficacy and fewer side effects, thus driving its adoption among oncologists worldwide.
Political: Regulations on clinical trials and approval process for new cell therapies vary across regions. Favourable regulatory guidelines around the world are expected to boost the industry growth.
Economic: The rising healthcare expenditure, increasing demand for advanced treatment options and growth of biotechnology industry are the major macroeconomic factors influencing the market.
Social: Growing public awareness about cell-based therapies and rising demand for personalized therapeutics are expected to positively impact the market.
Technological: Significant investments in R&D, development of better cell processing techniques, and advancements in genome editing tools like CRISPR are facilitating novel product development.
The Global Personalized Cell Therapy Market Size is expected to witness high growth owing to the rising incidences of cancer and other chronic diseases.
Regionally, North America dominates the market currently due to favourable regulatory environment and high adoption of advanced therapeutics. Europe is also observing significant demand for personalized medicine approaches like cell therapy.
Key players operating in the personalized cell therapy are Continental AG, Valeo, Robert Bosch, Denso Corporation, Magna International, Ficosa, ZF Friedrichshafen, Gentex, Aptiv, Renesas Electronics. Continental AG and Robert Bosch are the leading automotive component suppliers focusing on development of advanced driver assistance systems.
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it